Oppenheimer Asset Management Inc. bought a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 5,259 shares of the medical device company’s stock, valued at approximately $214,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in TNDM. Belpointe Asset Management LLC bought a new stake in Tandem Diabetes Care during the 4th quarter valued at approximately $26,000. GPS Wealth Strategies Group LLC bought a new stake in Tandem Diabetes Care during the 1st quarter valued at approximately $27,000. State of Wyoming raised its stake in Tandem Diabetes Care by 45.8% during the 4th quarter. State of Wyoming now owns 821 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 258 shares during the period. Quadrant Capital Group LLC raised its stake in Tandem Diabetes Care by 53.5% during the 4th quarter. Quadrant Capital Group LLC now owns 841 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 293 shares during the period. Finally, CoreCap Advisors LLC bought a new stake in Tandem Diabetes Care during the 4th quarter valued at approximately $50,000.
Tandem Diabetes Care Price Performance
TNDM opened at $28.51 on Thursday. The business has a fifty day moving average of $28.97 and a 200 day moving average of $33.39. Tandem Diabetes Care, Inc. has a 52-week low of $23.60 and a 52-week high of $59.91. The company has a quick ratio of 3.53, a current ratio of 4.38 and a debt-to-equity ratio of 0.86. The stock has a market cap of $1.86 billion, a P/E ratio of -8.19 and a beta of 0.92.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on TNDM. Wells Fargo & Company reduced their price objective on Tandem Diabetes Care from $40.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, August 4th. Craig Hallum reduced their price objective on Tandem Diabetes Care from $74.00 to $50.00 in a research note on Tuesday, June 13th. StockNews.com began coverage on Tandem Diabetes Care in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. TD Cowen reduced their price objective on Tandem Diabetes Care from $52.00 to $34.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Finally, Robert W. Baird reduced their price objective on Tandem Diabetes Care from $33.00 to $32.00 and set a “neutral” rating on the stock in a research note on Monday, August 21st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $46.80.
Check Out Our Latest Analysis on Tandem Diabetes Care
Tandem Diabetes Care Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Recommended Stories
- Five stocks we like better than Tandem Diabetes Care
- How Can Investors Benefit From After-Hours Trading
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- Why is the Ex-Dividend Date Significant to Investors?
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- How to Use the MarketBeat Stock Split Calculator
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
